Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Sissung Website

Tristan Sissung, Ph.D., M.S.

Selected Publications

1)  Goldspiel BR, Flegel WA, Dipatrizio G, Sissung T, Adams SD, Penzak SR, Biesecker LG, Fleisher TA, Patel JJ, Herion D, Figg WD, Lertora JJ, McKeeby JW.
Integrating pharmacogenetic information and clinical decision support into the electronic health record.
J Am Med Inform Assoc. 21: 522-8, 2014.
2)  Gao R, Reece KM, Sissung T, Fu SH, Venzon DJ, Reed E, Spencer SD, Price DK, Figg WD.
Are race-specific ERCC1 haplotypes in melanoma cases versus controls related to the predictive and prognostic value of ERCC1 N118N?.
BMJ Open. 3, 2013.
3)  Noonan AM, Eisch RA, Liewehr DJ, Sissung TM, Venzon DJ, Flagg TP, Haigney MC, Steinberg SM, Figg WD, Piekarz RL, Bates SE.
Electrocardiographic studies of romidepsin demonstrate its safety and identify a potential role for K(ATP) channel.
Clin. Cancer Res. 19: 3095-104, 2013.
4)  Figg WD, Chau CH, Madan RA, Gulley JL, Gao R, Sissung TM, Spencer S, Beatson M, Aragon-Ching J, Steinberg SM, Dahut WL.
Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: a pharmacogenetic assessment of outcome and toxicity.
Clin Genitourin Cancer. 11: 229-37, 2013.
5)  Sissung TM, Reece KM, Spencer S, Figg WD.
Contribution of the OATP1B subfamily to cancer biology and treatment.
Clin. Pharmacol. Ther. 92: 658-60, 2012.
6)  Pratt E, Sissung TM, Figg WD.
Loss of OATP1B3 function causes Rotor syndrome: Implications for potential use of inhibitors in cancer.
Cancer Biol. Ther. 13, 2012.
7)  Troutman SM, Sissung TM, Cropp CD, Venzon DJ, Spencer SD, Adesunloye BA, Huang X, Karzai FH, Price DK, Figg WD.
Racial disparities in the association between variants on 8q24 and prostate cancer: a systematic review and meta-analysis.
Oncologist. 17: 312-20, 2012.
8)  Peer CJ, Sissung TM, Kim A, Jain L, Woo S, Gardner ER, Kirkland CT, Troutman SM, English BC, Richardson ED, Federspiel J, Venzon D, Dahut W, Kohn E, Kummar S, Yarchoan R, Giaccone G, Widemann B, Figg WD.
Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia.
Clin. Cancer Res. 18: 2099-107, 2012.
9)  Sissung TM, Troutman SM, Campbell TJ, Pressler HM, Sung H, Bates SE, Figg WD.
Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy.
Discov Med. 13: 19-34, 2012.
10)  Peer CJ, Sissung TM, Figg WD.
CHIP and gp78-mediated ubiquitination of CYP3A4: Implications for the pharmacology of anticancer agents.
Cancer Biol. Ther. 11: 549-51, 2011.
Click Here to View Expanded Bibliography.

This page was last updated on 4/15/2014.